FUP Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Fuji Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥9.15 |
| 52 Week High | JP¥12.60 |
| 52 Week Low | JP¥7.05 |
| Beta | 0.25 |
| 1 Month Change | -4.69% |
| 3 Month Change | 18.06% |
| 1 Year Change | -26.21% |
| 3 Year Change | 18.83% |
| 5 Year Change | -19.74% |
| Change since IPO | 394.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| FUP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.2% | 4.4% | 2.0% |
| 1Y | -26.2% | -5.8% | 15.2% |
Return vs Industry: FUP underperformed the German Pharmaceuticals industry which returned -9.1% over the past year.
Return vs Market: FUP underperformed the German Market which returned 14.1% over the past year.
Price Volatility
| FUP volatility | |
|---|---|
| FUP Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FUP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FUP's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 1,658 | Shuhei Morita | www.fujipharma.jp |
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women, in vitro diagnostics, acute medical care products, and curative medicines, as well as information regarding pharmaceuticals and health; and contract manufacturing services.
Fuji Pharma Co., Ltd. Fundamentals Summary
| FUP fundamental statistics | |
|---|---|
| Market cap | €225.84m |
| Earnings (TTM) | €38.29m |
| Revenue (TTM) | €287.44m |
5.9x
P/E Ratio0.8x
P/S RatioIs FUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUP income statement (TTM) | |
|---|---|
| Revenue | JP¥46.14b |
| Cost of Revenue | JP¥28.29b |
| Gross Profit | JP¥17.84b |
| Other Expenses | JP¥11.70b |
| Earnings | JP¥6.15b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 252.79 |
| Gross Margin | 38.68% |
| Net Profit Margin | 13.32% |
| Debt/Equity Ratio | 52.6% |
How did FUP perform over the long term?
See historical performance and comparisonDividends
3.1%
Current Dividend Yield17%
Payout RatioDoes FUP pay a reliable dividends?
See FUP dividend history and benchmarks| Fuji Pharma dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 03 2025 |
| Days until Ex dividend | 56 days |
| Days until Dividend pay date | 123 days |
Does FUP pay a reliable dividends?
See FUP dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 10:41 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fuji Pharma Co., Ltd. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yoshinaga Toshiaki | Aizawa Securities Co. Ltd. |
| Masao Yoshida | Ichiyoshi Research Institute Inc. |
| Shigekazu Ishida | Marusan Securities Co. Ltd. |